Denmark· DK-28105089112
Fyremadel
A ganirelix product containing ganirelixacetat, registered in Denmark by SUN Pharmaceutical Industries Europe BV. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ganirelix is registered in 17 of 19 countries.
Countries holding a registration under ATC H01CC01 (ganirelix), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Ganirelix · ATC H01CC01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Ganirelixacetat
- Manufacturer
- SUN Pharmaceutical Industries Europe BV
- Country
- Denmark (DK)
- ATC code
- H01CC01
- ATC class
- Ganirelix
- Defined daily dose
- 0.25 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105089112
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
7 interactions on record for ganirelix.
Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ganirelix · interactions on record
7 records
- 7 moderate
Most severe, free to view
- Chorionic gonadotrophinG03GA01moderate
- Menotropin HMGG03GA02moderate
- UrofollitropinG03GA04moderate
- GonadorelinH01CA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H01CC01
Ganirelix, as other registers publish it.
- SpainASTARTE 0,25 MG/0,5 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA EFGGp Pharm S.A.
- United StatesFyremadelFerring Pharmaceuticals Inc.
- FinlandFyremadelSun Pharmaceutical Industries Europe B.V.
- NorwayFyremadelSun Pharmaceutical - Nederland
- GermanyFyremadelSun Pharmaceuticals Germany Gmbh
- PolandFyremadelSun Pharmaceutical Industries Europe B.V.
- SpainFYREMADEL 0,25 MG / 0,5 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA EFGSun Pharmaceutical Industries (Europe) B.V.
- FranceFYREMADEL 0,25 mg/0,5 mL, solution injectable en seringue pré-remplieSUN PHARMACEUTICAL INDUSTRIES EUROPE (PAYS BAS)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/edffa195-6be2-46a9-a0b5-47afe1c44c27 GET /v1/drugs/edffa195-6be2-46a9-a0b5-47afe1c44c27?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt injektionssprøjte",
"source": "dkma",
"strength": "0,25 mg/0,5 ml",
"auth_role": "CMS",
"dk_drugid": "28105089112",
"substance": "Ganirelixacetat",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": true,
"registration_date_serial": "41421"
}See everything about ganirelix.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.